Properties and status of dabigatran, rivaroxaban, and apixaban.
| . | Dabigatran . | Rivaroxaban . | Apixaban . |
|---|---|---|---|
| Target | Thrombin | Xa | Xa |
| Time to peak level, hr | 2–3 | 3 | 3 |
| Half-life, hr | 12–17 | 5–9 | 9–14 |
| Bioavailability, % | 6 | 80 | >50 |
| Renal excretion, % | 80 | 66 | 25 |
| Dosing | Oral, once or twice daily | Oral, once or twice daily | Oral, once or twice daily |
| Status | Approved in Europe for prophylaxis after TKR and THR. Phase III studies ongoing | Phase III development | Phase III development |
| . | Dabigatran . | Rivaroxaban . | Apixaban . |
|---|---|---|---|
| Target | Thrombin | Xa | Xa |
| Time to peak level, hr | 2–3 | 3 | 3 |
| Half-life, hr | 12–17 | 5–9 | 9–14 |
| Bioavailability, % | 6 | 80 | >50 |
| Renal excretion, % | 80 | 66 | 25 |
| Dosing | Oral, once or twice daily | Oral, once or twice daily | Oral, once or twice daily |
| Status | Approved in Europe for prophylaxis after TKR and THR. Phase III studies ongoing | Phase III development | Phase III development |